23.18
1.13 (5.12%)
| Previous Close | 22.05 |
| Open | 22.18 |
| Volume | 1,773,754 |
| Avg. Volume (3M) | 1,327,058 |
| Market Cap | 2,868,027,392 |
| Price / Sales | 9.70 |
| Price / Book | 6.56 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -277.30% |
| Operating Margin (TTM) | -435.71% |
| Diluted EPS (TTM) | -4.23 |
| Quarterly Revenue Growth (YOY) | -80.70% |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | -300.00 M |
| Levered Free Cash Flow (TTM) | -174.00 M |
| Return on Assets (TTM) | -22.25% |
| Return on Equity (TTM) | -63.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arcus Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.10 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 34.93% |
| % Held by Institutions | 64.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 30 Sep 2025 | 31,424,760 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (Citigroup, 141.59%) | Buy |
| Median | 30.50 (31.58%) | |
| Low | 16.00 (Goldman Sachs, -30.98%) | Hold |
| Average | 33.00 (42.36%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 19.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2025 | 32.00 (38.05%) | Buy | 21.53 |
| 29 Oct 2025 | 28.00 (20.79%) | Buy | 20.29 | |
| B of A Securities | 28 Nov 2025 | 26.00 (12.17%) | Hold | 26.10 |
| Goldman Sachs | 30 Oct 2025 | 16.00 (-30.97%) | Hold | 20.19 |
| Citigroup | 29 Oct 2025 | 56.00 (141.59%) | Buy | 20.29 |
| 13 Oct 2025 | 54.00 (132.96%) | Buy | 16.64 | |
| Wells Fargo | 20 Oct 2025 | 29.00 (25.11%) | Buy | 17.47 |
| Truist Securities | 07 Oct 2025 | 39.00 (68.25%) | Buy | 14.03 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZOY ALEXANDER | - | 22.16 | -8,832 | -195,327 |
| GOELTZ II ROBERT C. | - | 22.24 | -12,662 | -281,573 |
| JAEN JUAN C. | - | 22.24 | -21,208 | -471,616 |
| JARRETT JENNIFER | - | 22.24 | -21,208 | -471,616 |
| MARKUS RICHARD | - | 22.24 | -9,546 | -212,281 |
| ROSEN TERRY J | - | 22.24 | -54,691 | -1,216,200 |
| TANG CAROLYN C. | - | 22.24 | -14,468 | -321,734 |
| Aggregate Net Quantity | -142,615 | |||
| Aggregate Net Value ($) | -3,170,348 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.22 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AZOY ALEXANDER | Officer | 18 Dec 2025 | Automatic sell (-) | 4,343 | 21.99 | 95,503 |
| ROSEN TERRY J | Officer | 17 Dec 2025 | Sell (-) | 25,744 | 22.28 | 573,576 |
| JAEN JUAN C. | Officer | 17 Dec 2025 | Sell (-) | 9,983 | 22.28 | 222,421 |
| JARRETT JENNIFER | Officer | 17 Dec 2025 | Sell (-) | 9,983 | 22.28 | 222,421 |
| GOELTZ II ROBERT C. | Officer | 17 Dec 2025 | Sell (-) | 5,960 | 22.28 | 132,789 |
| AZOY ALEXANDER | Officer | 17 Dec 2025 | Sell (-) | 2,113 | 22.28 | 47,078 |
| TANG CAROLYN C. | Officer | 17 Dec 2025 | Sell (-) | 6,810 | 22.28 | 151,727 |
| MARKUS RICHARD | Officer | 17 Dec 2025 | Sell (-) | 4,494 | 22.28 | 100,126 |
| ROSEN TERRY J | Officer | 16 Dec 2025 | Sell (-) | 28,947 | 22.20 | 642,623 |
| JAEN JUAN C. | Officer | 16 Dec 2025 | Sell (-) | 11,225 | 22.20 | 249,195 |
| JARRETT JENNIFER | Officer | 16 Dec 2025 | Sell (-) | 11,225 | 22.20 | 249,195 |
| GOELTZ II ROBERT C. | Officer | 16 Dec 2025 | Sell (-) | 6,702 | 22.20 | 148,784 |
| AZOY ALEXANDER | Officer | 16 Dec 2025 | Sell (-) | 2,376 | 22.20 | 52,747 |
| TANG CAROLYN C. | Officer | 16 Dec 2025 | Sell (-) | 7,658 | 22.20 | 170,008 |
| MARKUS RICHARD | Officer | 16 Dec 2025 | Sell (-) | 5,052 | 22.20 | 112,154 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |